Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Association between serum C-reactive protein and albumin levels and psychiatric comorbidities in liver transplant recipients.

Lin CC, Chen CC, Chen CL, Huang TL.

Transplant Proc. 2013 Jul-Aug;45(6):2337-40. doi: 10.1016/j.transproceed.2013.03.023.

PMID:
23953546
2.

Elevation of C-reactive protein level and its correlation with psychiatric comorbidities in recipients after liver transplantation.

Chen CC, Hsu LW, Nakano T, Goto S, Chen CL.

Transplant Proc. 2014 Apr;46(3):894-6. doi: 10.1016/j.transproceed.2013.12.030.

PMID:
24767374
3.

Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study.

Cardoso FS, Bagshaw SM, Abraldes JG, Kneteman NM, Meeberg G, Fidalgo P, Karvellas CJ.

Ann Hepatol. 2015 Jul-Aug;14(4):505-14.

4.

Serum leptin and insulin in paediatric end-stage liver disease and following successful orthotopic liver transplantation.

Roberts GA, Holt RI, Ghatei MA, Baker AJ, Bloom SR, Miell JP.

Clin Endocrinol (Oxf). 1998 Apr;48(4):401-6.

PMID:
9640405
5.
6.

Model for end-stage liver disease score versus simplified acute physiology score criteria in acute renal failure after liver transplantation.

Umbro I, Tinti F, Mordenti M, Rossi M, Ianni S, Pugliese F, Ruberto F, Ginanni Corradini S, Nofroni I, Poli L, Berloco PB, Mitterhofer AP.

Transplant Proc. 2011 May;43(4):1139-41. doi: 10.1016/j.transproceed.2011.02.045.

PMID:
21620072
7.

A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation.

King A, Masterton G, Gunson B, Olliff S, Redhead D, Mangat K, Oniscu G, Hayes P, Tripathi D.

Liver Transpl. 2011 Jul;17(7):771-8. doi: 10.1002/lt.22281.

8.

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept.

Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP.

Transpl Int. 2011 Jan;24(1):91-9. doi: 10.1111/j.1432-2277.2010.01161.x. Epub 2010 Sep 3.

9.

Prediction of gross post-transplant outcomes based on the intra-operative decline in C-reactive protein in living donor liver transplantation.

Chung HS, Kim ES, Park JH, Park CS.

Transplant Proc. 2015 Mar;47(2):431-7. doi: 10.1016/j.transproceed.2015.01.005.

PMID:
25769586
10.

Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.

An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, You YK, Kim DG, Jung ES.

Liver Transpl. 2012 Dec;18(12):1406-14. doi: 10.1002/lt.23512.

11.

Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease.

Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, Levey AS, Sarnak MJ.

Am J Kidney Dis. 2003 Jul;42(1):44-52.

PMID:
12830455
12.

Predicting the discharge status after liver transplantation at a single center: a new approach for a new era.

Kelly DM, Bennett R, Brown N, McCoy J, Boerner D, Yu C, Eghtesad B, Barsoum W, Fung JJ, Kattan MW.

Liver Transpl. 2012 Jul;18(7):796-802. doi: 10.1002/lt.23434.

13.

Significance of high C-reactive protein levels in pre-dialysis patients.

Ortega O, Rodriguez I, Gallar P, Carreño A, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Vigil A.

Nephrol Dial Transplant. 2002 Jun;17(6):1105-9.

PMID:
12032204
14.

Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.

Snaedal S, Heimbürger O, Qureshi AR, Danielsson A, Wikström B, Fellström B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Bárány P.

Am J Kidney Dis. 2009 Jun;53(6):1024-33. doi: 10.1053/j.ajkd.2009.02.008. Epub 2009 Apr 25.

PMID:
19394732
15.

Donor age does not influence 12-month outcome after orthotopic liver transplantation.

Faber W, Seehofer D, Puhl G, Guckelberger O, Bertram C, Neuhaus P, Bahra M.

Transplant Proc. 2011 Dec;43(10):3789-95. doi: 10.1016/j.transproceed.2011.10.048.

PMID:
22172848
16.

The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center.

Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt C, Harlander-Locke M, Hong JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW.

Ann Surg. 2013 Sep;258(3):409-21. doi: 10.1097/SLA.0b013e3182a15db4.

17.

Modified Charlson Comorbidity Index in predicting early mortality after liver transplantation.

Wasilewicz M, Raszeja-Wyszomirska J, Wunsch E, Wójcicki M, Milkiewicz P.

Transplant Proc. 2009 Oct;41(8):3117-8. doi: 10.1016/j.transproceed.2009.07.097.

PMID:
19857690
18.

Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients.

Kaysen GA, Greene T, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, Levin NW, Yan G; HEMO Study Group.

Am J Kidney Dis. 2003 Dec;42(6):1200-11.

PMID:
14655192
19.

High mortality in orthotopic liver transplant recipients who require hemodialysis.

Zand MS, Orloff MS, Abt P, Patel S, Tsoulfas G, Kashyap R, Jain A, Safadjou S, Bozorgzadeh A.

Clin Transplant. 2011 Mar-Apr;25(2):213-21. doi: 10.1111/j.1399-0012.2010.01238.x.

PMID:
20331690
20.

C-reactive protein and the Framingham coronary risk score in patients newly diagnosed with intermittent claudication: a prospective study.

Shahin Y, Hatfield J, Chetter I.

Vasc Endovascular Surg. 2012 Apr;46(3):242-5. doi: 10.1177/1538574412438062. Epub 2012 Apr 1.

PMID:
22474034

Supplemental Content

Support Center